Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 11/20 | 0.83 |
| ▸ | PDE4D | Q08499 | 11/20 | 0.51 |
| ▸ | PDE4A | P27815 | 6/20 | 0.51 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4365705 | 0.91 | PDE4B (1.00) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL4370781 | 0.87 | PDE4B (0.75) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL4370214 | 0.86 | PDE4B (0.80) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL4379192 | 0.85 | PDE4B (0.60) | PDE4BHTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL4363586 | 0.83 | PDE4B (0.80) | PDE4BPDE4DPDE4APDE4CHTR1A | |
| SCHEMBL4369697 | 0.83 | PDE4B (0.83) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL4368288 | 0.82 | PDE4B (0.78) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL4368584 | 0.82 | PDE4B (0.83) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL4369695 | 0.82 | PDE4B (0.67) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL4361797 | 0.76 | PDE4B (0.74) | PDE4BPDE4DPDE4APDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291950-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | KALYPSYS, INC. (US) | 2009-11-26 | — | — | US | disclosed |
| US-20090291950-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | KALYPSYS, INC. (US) | 2009-11-26 | — | — | US | disclosed |
| US-20090291950-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | KALYPSYS, INC. (US) | 2009-11-26 | — | — | US | disclosed |
| WO-2008006052-A2 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | GOVEK STEVEN P (US) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291950-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | PDE4B 2/4885PDE4D 4/4885PDE4A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.